Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.59 |
| ▸ | FPR3 | P25089 | 3/20 | 0.58 |
| ▸ | FPR2 | P25090 | 3/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31188356 | 1.00 | NPC1 (0.77) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL10092397 | 1.00 | NPC1 (0.77) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL2709482 | 0.97 | NPC1 (0.72) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL206295 | 0.97 | NPC1 (0.72) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL31148235 | 0.96 | NPC1 (0.72) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL14323243 | 0.91 | NPC1 (0.65) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL14323244 | 0.91 | NPC1 (0.65) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL17474788 | 0.90 | NPC1 (0.80) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL17474759 | 0.90 | NPC1 (0.80) | NPC1KMT2AMEN1LMNANPSR1 | |
| SCHEMBL23373363 | 0.89 | NPC1 (0.79) | NPC1KMT2AMEN1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437113-B | Thiazolopyridine cyclotriazole compound, and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-114437113-A | Thiazolopyridine ring-linked triazole compound and preparation method and application thereof | 西安交通大学 | 2022-05-06 | — | — | CN | disclosed |
| EP-2791161-B1 | INHIBITORS OF HCV NS5A | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2791161-A1 | INHIBITORS OF HCV NS5A | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2013087743-A1 | INHIBITORS OF HCV NS5A | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-1671949-B1 | Substituted Pyridinylamines | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267118-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | NPC1 2106/4885KMT2A 4341/4885MEN1 880/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | NPC1 1830/4885KMT2A 4286/4885MEN1 726/4885 |
| US-20050250815-A1 | Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade | F12, TFPI, F11 | NPC1 2278/4885KMT2A 4412/4885MEN1 990/4885 |
| US-20060264626-A1 | INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | NPC1 3091/4885KMT2A 4164/4885MEN1 842/4885 |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HAVCR2, EIF2AK2, MAVS | NPC1 59/4885KMT2A 4036/4885MEN1 4874/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NPC1 34/4885KMT2A 2992/4885MEN1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.